Neogen Chemicals raises ₹600 crore via QIP at ₹2,255 per share
- Neogen Chemicals raised ₹599.99 crore via its maiden QIP
- The issue was oversubscribed 6.5x by institutional investors
- Shares were allotted at ₹2,255 each, above the floor price
- Proceeds will fund debt repayment and working capital needs
- Paid-up capital increases to ₹30.04 crore post-allotment
*this image is generated using AI for illustrative purposes only.
Neogen Chemicals completed its first-ever qualified institutional placement (QIP) on September 16, 2026, raising ₹5,99,99,98,015. The issue was oversubscribed 6.5x, reflecting strong demand from marquee domestic and global institutional investors.
The company allotted 26,60,753 equity shares at ₹2,255 per share. This price includes a premium of ₹2,245 over the face value of ₹10 and is above the floor price of ₹2,189.73 set on September 10, 2026.
Pricing and Regulatory Framework
The final issue price was determined in consultation with lead managers Inga Ventures Private Limited, IIFL Capital Services Limited, and Kotak Mahindra Capital Company Limited. Trilegal acted as legal counsel to the company, while JSA Advocates & Solicitors advised the lead managers.
The QIP was conducted under Chapter VI of the SEBI ICDR Regulations and Sections 42 and 62 of the Companies Act, 2013. The preliminary placement document was approved on September 10, 2026, and the final document dated September 16, 2026, was filed with BSE Limited and the National Stock Exchange of India Limited.
| Parameter | Detail |
|---|---|
| Issue Price | ₹2,255 per share |
| Shares Allotted | 26,60,753 |
| Total Proceeds | ₹5,99,99,98,015 |
| Oversubscription | 6.5x |
| Face Value | ₹10 per share |
| Floor Price (Sep 10) | ₹2,189.73 per share |
| Closure Date | September 16, 2026 |
Allotment Details
The Board of Directors initially approved the issue on July 24, 2026, with shareholder approval via special resolution on August 21, 2026. The allotment increases paid-up equity share capital from ₹27,38,16,740 (2,73,81,674 shares) to ₹30,04,24,270 (3,00,42,427 shares).
Major allottees receiving more than 5% of the equity shares offered include:
| Allottee Category | Name of Allottee | Shares Allotted | % of Issue |
|---|---|---|---|
| Mutual Fund | ICICI Prudential Multi Cap Fund | 2,21,730 | 8.33% |
| Custodian MF | Invesco India Small Cap Fund | 3,16,757 | 11.90% |
| Insurance | SBI Life Insurance Co. Ltd | 3,54,768 | 13.33% |
| FPI | Abu Dhabi Investment Authority - Way | 1,41,907 | 5.33% |
Other significant investors include ICICI Prudential Commodities Fund, ICICI Prudential Mid Cap Fund, Mirae Asset funds, WhiteOak Capital funds, and Axis Mutual Fund schemes.
Strategic Implications
Proceeds will be utilized for repayment or pre-payment of borrowings, funding long-term working capital requirements, and general corporate purposes. This aims to reduce outstanding indebtedness, lower debt servicing costs, and improve the debt-to-equity ratio.
Dr. Harin Kanani, Managing Director, stated that the raise enabled the company to secure more equity in a single transaction than across all seven years since listing. He noted that strengthening the balance sheet enhances financial flexibility as the company transitions from capital deployment to operational execution in advanced battery materials.
Historical Stock Returns for Neogen Chemicals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.43% | +0.18% | +14.11% | +103.83% | +63.48% | +101.72% |
How will the reduction in debt servicing costs impact Neogen Chemicals' projected EBITDA margins over the next two fiscal years?
Given the 6.5x oversubscription, what is the likelihood of Neogen conducting another equity raise in the near term to fund its advanced battery materials expansion?
How might the significant entry of FPIs like Abu Dhabi Investment Authority influence the company's valuation multiples compared to domestic peers?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
